摘要
目的探讨布地奈德联合福莫特罗雾化吸入治疗慢性阻塞性肺疾病(COPD)的效果及其对患者肺功能和炎性递质的影响。方法抽取2015年1月至2016年1月驻马店中心医院收治的96例COPD患者,根据用药方案分为对照组(n=48)和观察组(n=48)。对照组患者给予布地奈德吸入治疗,每次1吸,每日3次;观察组患者在对照组治疗的基础上给予福莫特罗雾化吸入,每次4.5μg,每日3次;2组患者均持续治疗3个月。观察2组患者临床疗效、不良反应发生率,比较2组患者治疗前后1 s用力呼气容积(FEV1)、FEV1与用力肺活量(FVC)比值(FEV1/FVC)、FEV1占预测值百分比(FEV1%)、动脉血二氧化碳分压(PaCO_2)、动脉血氧分压(PaO_2)、肿瘤坏死因子-α(TNF-α)及白细胞介素-8(IL-8)水平的差异。结果治疗前2组患者FEV1、FEV1/FVC、FEV1%、PaCO_2、PaO_2、TNF-α、IL-8水平比较差异均无统计学意义(P>0.05)。2组患者治疗后FEV1、PaO_2显著高于治疗前(P<0.05),PaCO_2、TNF-α、IL-8水平显著低于治疗前(P<0.05);治疗后,观察组患者FEV1、PaO_2水平显著高于对照组(P<0.05),FEV1/FVC、FEV1%、PaCO_2、TNF-α、IL-8水平显著低于对照组(P<0.05)。观察组患者治疗总有效率(95.83%)显著高于对照组(77.08%)(χ~2=7.207,P<0.05);观察组患者不良反应发生率(8.33%)与对照组(10.42%)比较差异无统计学意义(χ~2=0.000,P>0.05)。结论布地奈德联合福莫特罗治疗COPD患者疗效确切,可有效改善患者肺部功能,减少炎性因子释放量,且不增加不良反应发生率,具有一定安全性。
Objective To explore the curative effect of the budesonide and formoterol inhalation on chronic obstructive pulmonary disease （COPD） and its effect on pulmonary function and inflammatory mediators. Methods Ninty-six patients with COPD in the Central Hospital of Zhumadian City from January 2015 to January 2016 were selected. According to the dif- ferent treatment plan, they were divided into control group （ n = 48 ） and observation group （ n = 48 ）. The patients in the con- trol group were only treated with budesonide, every time one suction, three times a day. Based on the usage of the control group, the patients in the observation group was treated with formoterol, every time 4.5 μg, three times a day. The two groups were treated for three months. The clinical efficacy and adverse reaction rate of two groups were statistically analyzed, and the changes of one second forced expiratory volume （FEV1） ,FEV1 and FEV1/foreed vital capacity（FVC） ,FEV1% ,arterial car- bon dioxide （ PaCO2 ）, arterial oxygen pressure （ PaO2 ）, the level tumor necrosis factor alpha （TNF-a） and interleukin-8 （ IL- 8 ） were compared between the two groups before and after treatment. Results There was no significant difference in the FEV1, FEV1/FVC, FEV 1% , PaCO2 , PaO2,TNF-α, IL-8 between the two groups before treatment （ P 〉 0.05 ）. Afier treatment, the levels of FEVl and PaO2 in the two groups were higher than those before treatment（P 〈0.05） ,and the levels of PaCO2 , TNF-α ,IL-8 were lower than those before treatment（P 〈 0.05 ）. After treatment,the levels of FEV1 and PaO2 in the observa- tion group were higher than those in the control group（ P 〈 0. 05 ） , while the levels of FEV1/FVC, FEV1% , PaCO2 ,TNF-α and IL-8 were lower than those in the control group （P 〈 0.05 ）. The total effective rate of the observation group （95.83 % ） was significantly higher than that of the control group （77.08%） （χ2 = 7. 207,P 〈 0.05 ）. The was no significant difference in the incidence rate of adverse reaction in the observation group （8.33%） compared with the control group （10.42%） （χ2 = 0. 000,P 〉 0. 05 ）. Conclusion The curative effect of budesonide and formoterol in treating patients with COPD is exact, it can effectively improve lung function, reduce the release of inflammatory factors, improve the therapeutic effect, and does not in- crease the incidence of adverse reactions. It has certain safety.
出处
《新乡医学院学报》
CAS
2017年第10期932-935,共4页
Journal of Xinxiang Medical University
关键词
布地奈德
福莫特罗
慢性阻塞性肺疾病
肺功能
炎性递质
budesonide
formoterol
chronic obstructive pulmonary disease
pulmonary function
inflammatory mediators
